Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Study confirms inverse association of increase in BMI with lower brain volumes

Researchers from Boston University School of Medicine determined that excess abdominal fat places otherwise healthy, middle-aged people at risk for dementia later in life. Preliminary findings suggest a relationship between obesity and dementia that could lead to promising prevention strategies in the future. Results of this study are published early online in Annals of Neurology, a journal of the American Neurological Association.

20 May 2010

Diabetic patients with limited health literacy are at higher risk for hypoglycemia: Study

People with diabetes who have limited health literacy are at higher risk for hypoglycemia or low blood sugar, according to a new study from researchers at the University of California, San Francisco and the Kaiser Permanente Division of Research in Oakland, CA.

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

Sleep apnea increases insulin resistance: Study

Sleep apnea may cause metabolic changes that increase insulin resistance, according to researchers from the University of Pittsburgh Medical Center. The intermittent hypoxia associated with sleep apnea causes a distinct drop in insulin sensitivity in mice, even though chronic hypoxia, such as that associated with high altitude, did not.

18 May 2010

Woman with higher blood levels of IGF-I more likely to develop breast cancer: Study

Women who have high blood levels of a hormone called insulin-like growth factor-I are more likely to develop breast cancer, according to a Cancer Research UK study published in the Lancet Oncology today (Monday).

18 May 2010

Halozyme announces voluntary HYLENEX product recall

Halozyme Therapeutics, Inc. today announced that Halozyme and Baxter have confirmed the presence of small flake-like glass particles in a limited number of vials of HYLENEX® (hyaluronidase human injection) product at the Baxter manufacturing facility. Earlier today, Halozyme notified the U.S. Food and Drug Administration that it is voluntarily recalling affected lots of 150U HYLENEX product from distribution.

17 May 2010

Halozyme Therapeutics announces delivery of notice of breach to Baxter Healthcare

Halozyme Therapeutics, Inc. today announced the delivery of a notice of breach to Baxter Healthcare Corporation due to Baxter's failure to provide HYLENEX (hyaluronidase human injection) in accordance with the terms of the parties' existing development and supply contracts.

17 May 2010

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Saint John's Health Center Trustee and philanthropist Patrick Soon-Shiong, M.D., who developed the first FDA-approved protein nanoparticle treatment for cancer, has received the 2010 Distinguished Medical Science Award from the Friends of the National Library of Medicine for his significant contributions to the research and treatment of diabetes and cancer.

15 May 2010

Researchers identify protein involved in pushing bladder tumors to become invasive

Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become invasive - and deadly.

15 May 2010

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

By 2020, new cases of Type 1 diabetes in children younger than five are expected to double if current trends continue, according to a study published in The Lancet. Diabetes is an epidemic, with numbers of those suffering from diabetes and its complications increasing worldwide.

14 May 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

RYGB surgery increases insulin activity in diabetes mellitus patients

Diabetes mellitus is a chronic metabolic disease resulted from, either decreased production of insulin or increased resistance to it from peripheral tissues or both factors combined together. While medical treatment remains the mainstay of treatment for diabetes, some surgical procedures, such as Roux-en-Y gastric bypass, have demonstrated some potential to be a treatment option for diabetes.

13 May 2010

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

Study: Treating serious gum disease in diabetics can help lower blood sugar levels

Researchers have found that reducing inflammation of the gums in people with diabetes can help lower the risk of serious complications associated with the condition, such as eye problems and heart disease.

13 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

A study to be published in the latest issue of The Cochrane Library and led by researchers at the University of Edinburgh and supported by colleagues at the Peninsula Dental School, the University of Ottawa and UCL Eastman Dental Institute, suggests that the treatment of serious gum (periodontal) disease in diabetics with Type 2 diabetes may lower their blood sugar levels.

12 May 2010

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes who have preexisting gum disease.

12 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Insulin News and Research

Further Reading

Study confirms inverse association of increase in BMI with lower brain volumes

Diabetic patients with limited health literacy are at higher risk for hypoglycemia: Study

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Sleep apnea increases insulin resistance: Study

Woman with higher blood levels of IGF-I more likely to develop breast cancer: Study

Halozyme announces voluntary HYLENEX product recall

Halozyme Therapeutics announces delivery of notice of breach to Baxter Healthcare

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Researchers identify protein involved in pushing bladder tumors to become invasive

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

Increased IR associated with HCC development in chronic HCV-infected patients

RYGB surgery increases insulin activity in diabetes mellitus patients

Additional benefits of LAIAs over long-acting human insulin not been proven

Study: Treating serious gum disease in diabetics can help lower blood sugar levels

Merck hosts R&D and Business Briefing

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

Transition Therapeutics reports increased revenue in third-quarter 2010

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News